Your Medications May Be Reshaping Your Gut Microbiome as You Age

The gut microbiome changes substantially as we age, with beneficial commensal bacteria declining and potentially harmful species increasing. But a critical question has gone largely unanswered: how much of what we call aging-associated microbiome change is actually driven by the diseases older people develop — or the medications they take to treat them? This large-scale computational study aimed to untangle exactly that.

Researchers at the Indraprastha Institute of Information Technology Delhi re-analyzed 45,454 gut microbiome samples from 141 published studies, comparing aging-associated microbial shifts against disease-associated signatures across six major disease categories. They then validated their findings using two independent population-level cohorts comprising 6,029 subjects.

The most striking finding was the identification of 15 microbes enriched during aging and depleted in healthy individuals. More than 50% of these belonged to oral bacterial clades — specifically Streptococcus, Veillonella, and Rothia. These bacteria are not native to the gut; their presence signals oral-to-gut microbial translocation. Crucially, these same oral microbes showed reproducible associations with seven cardiometabolic medications across the population cohorts, suggesting that drug use — rather than aging per se — may explain much of their enrichment.

Cardiometabolic diseases showed the greatest microbiome overlap with aging signatures, followed by colorectal cancer. This dose-response pattern implies that individuals managing these conditions with long-term medications may progressively accumulate oral microbes in the gut, compounding already-vulnerable microbiome states.

For clinicians and researchers, these findings carry important methodological implications: aging microbiome studies that fail to account for medication use risk misattributing drug effects to biological aging. For patients, it raises important questions about whether medication-induced microbiome disruption is modifiable. The authors propose deconfounding strategies to separate medication from disease effects in future aging microbiome research.